A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Solid Tumor, AdultRelapsed CancerRefractory Cancer
Interventions
DRUG

HST-1011

HST-1011 given orally

BIOLOGICAL

Cemiplimab

Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally

Trial Locations (14)

10087

Memorial Sloan Kettering Cancer Center, New York

10461

Montefiore Einstein Comprehensive Cancer Center, The Bronx

15232

University of Pittsburgh (UPMC), Hillman Cancer Center, Pittsburgh

19104

Abramson Cancer Center, Philadelphia

34232

Florida Cancer Specialists, Sarasota

77030

The University of Texas MD Anderson Cancer Center, Houston

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

97213

Providence Cancer Institute of Oregon, Portland

K1N 6N5

University of Ottawa, Ottawa

M5G 2M9

Princess Margaret Cancer Center, Toronto

Unknown

NEXT Oncology Barcelona IOB Hospital Quirónsalud, Barcelona

Clínica Universidad de Navarra, Madrid

NEXT Oncology Hospital Universitario Quirónsalud Madrid, Madrid

Clínica Universidad de Navarra (Pamplona), Pamplona

Sponsors
All Listed Sponsors
lead

HotSpot Therapeutics, Inc

INDUSTRY